Spero Therapeutics Inc. (SPRO)
$1.22
$-0.01
(-0.81%)
As on 26-Aug-2026 16:00EDT
Market cap
$70 Mln
Revenue (TTM)
$43 Mln
P/E Ratio
8.6
P/B Ratio
1.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
3.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$0.1
-
Face value
--
-
Shares outstanding
58,234,827
9 Years Aggregate
CFO
$-358.27 Mln
EBITDA
$-357.80 Mln
Net Profit
$-377.62 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Spero Therapeutics (SPRO)
| -47.6 | 2.5 | -55.8 | -34.1 | -1.6 | -40.9 | -- |
|
BSE Sensex*
| -9.1 | 1.1 | 1.2 | -4.8 | 5.8 | 6.6 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Spero Therapeutics (SPRO)
| 126.2 | -29.7 | -15.0 | -89.2 | -17.4 | 101.7 | 56.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Spero Therapeutics (SPRO)
|
1.2 | 70.5 | 43.0 | 7.4 | -17.1 | 14.3 | 8.6 | 1.6 |
| 89.1 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 250.3 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 79.2 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.1 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 107.1 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 538.9 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 619.1 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 377.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 151.5 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Spero Therapeutics (SPRO)
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates... include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Read more
-
Co-Founder & Chairman of the Board
Dr. Ankit Mahadevia M.D., MBA
-
Co-Founder & Chairman of the Board
Dr. Ankit Mahadevia M.D., MBA
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Spero Therapeutics (SPRO)
What is the current share price of Spero Therapeutics Inc (SPRO) Today?
The share price of Spero Therapeutics Inc (SPRO) is $1.22 (NASDAQ) as of 26-Aug-2026 16:00 EDT. Spero Therapeutics Inc (SPRO) has given a return of -1.59% in the last 3 years.
What is the current PB & PE ratio of Spero Therapeutics Inc (SPRO)?
The P/E ratio of Spero Therapeutics Inc (SPRO) is 8.64 times as on 21-Aug-2026.
The P/B ratio of Spero Therapeutics Inc (SPRO) is 1.59 times as on 21-Aug-2026, a 70 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
16.14 |
2.34 |
2024 |
-0.81 |
1.21 |
2023 |
3.42 |
0.73 |
2022 |
-1.82 |
1.11 |
2021 |
-5.73 |
5.83 |
What is the 52 Week High and Low of Spero Therapeutics Inc (SPRO)?
The 52-week high and low of Spero Therapeutics Inc (SPRO) are Rs 3.08 and Rs 1.08 as of 27-Aug-2026.
What is the market cap of Spero Therapeutics Inc (SPRO)?
Spero Therapeutics Inc (SPRO) has a market capitalisation of $ 70 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Spero Therapeutics Inc (SPRO)?
Before investing in Spero Therapeutics Inc (SPRO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.